TABLE OF CONTENTS
1 INTRODUCTION 53
1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT TYPE LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET END USER COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 75
4.1 PESTEL ANALYSIS 76
4.2 PORTER'S 5 FORCES 77
5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 78
5.1 REGULATORY SCENARIO IN THE U.S. 78
5.2 REGULATORY SCENARIO IN AUSTRALIA 79
5.3 REGULATORY SCENARIO IN JAPAN 79
5.4 REGULATORY SCENARIO IN CHINA 79
6 MARKET OVERVIEW 81
6.1 DRIVERS 83
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 83
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 85
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 85
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 86
6.2 RESTRAINTS 87
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 87
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 87
6.3 OPPORTUNITIES 88
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 88
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 88
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 89
6.4 CHALLENGES 90
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 90
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90
7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 91
7.1 OVERVIEW 92
7.2 INSTRUMENTS 95
7.2.1 BIOPSY INSTRUMENTS 96
7.2.1.1 BONE MARROW BIOPSY 96
7.2.1.2 NEEDLE BIOPSY 96
7.2.1.3 SURGICAL BIOPSY 96
7.2.1.4 OTHERS 97
7.2.2 PATHOLOGY-BASED INSTRUMENTS 97
7.2.2.1 PCR INSTRUMENTS 97
7.2.2.2 SLIDE STAINING SYSTEMS 97
7.2.2.3 TISSUE PROCESSING SYSTEMS 97
7.2.2.4 CELL PROCESSORS 97
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 98
7.2.3 IMAGING INSTRUMENTS 98
7.2.3.1 ULTRASOUND SYSTEMS 98
7.2.3.2 CT SYSTEMS 98
7.2.3.3 MRI SYSTEMS 98
7.2.3.4 OTHERS 98
7.2.4 OTHERS 98
7.3 CONSUMABLES & ACCESSORIES 99
7.3.1 KITS 100
7.3.1.1 PCR KITS 100
7.3.1.2 DNA POLYMERASE KITS 100
7.3.1.3 NUCLEIC ACID ISOLATION KITS 100
7.3.1.4 OTHERS 101
7.3.2 REAGENTS 101
7.3.2.1 ASSAYS 101
7.3.2.2 BUFFERS 101
7.3.2.3 PRIMERS 101
7.3.2.4 OTHERS 101
7.3.3 PROBES 102
7.3.4 OTHER CONSUMABLES 102
8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 103
8.1 OVERVIEW 104
8.2 BLOOD TEST 107
8.2.1 COMPLETE BLOOD COUNT (CBC) 108
8.2.2 BLOOD CHEMISTRY TESTS 108
8.2.3 OTHERS 108
8.3 IMAGING TEST 108
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 109
8.3.2 MRI 109
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 110
8.3.4 OTHERS 110
8.4 BONE MARROW TESTS 110
8.4.1 BONE MARROW ASPIRATE 111
8.4.2 BONE MARROW BIOPSY 111
8.4.3 OTHERS 111
8.5 GENETIC TESTS 111
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 112
8.5.2 KARYOTYPING 112
8.5.3 OTHERS 112
8.6 BIOMARKER TEST 112
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 114
8.7 IMMUNOPHENOTYPING 114
8.7.1 FLOW CYTOMETRY 115
8.7.2 IMMUNOHISTOCHEMISTRY 115
8.7.3 OTHERS 115
8.8 OTHERS 115
9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 117
9.1 OVERVIEW 118
9.2 MYELOBLASTIC (M0) 121
9.3 MYELOBLASTIC (M1) 121
9.4 MYELOBLASTIC (M2) 122
9.5 PROMYELOCYTIC (M3) 123
9.6 MYELOMONOCYTIC (M4) 124
9.7 MONOCYTIC (M5) 124
9.8 ERYTHROLEUKEMIA (M6) 125
9.9 MEGAKARYOCYTIC (M7) 126
10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127
10.1 OVERVIEW 128
10.2 65 AND ABOVE 131
10.3 30-65 131
10.4 BELOW 21 132
10.5 21-29 133
11 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 135
11.1 OVERVIEW 136
11.2 MALE 139
11.3 FEMALE 139
12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 141
12.1 OVERVIEW 142
12.2 HOSPITALS 145
12.3 ASSOCIATED LABS 145
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 146
12.5 DIAGNOSTIC IMAGING CENTERS 147
12.6 CANCER RESEARCH INSTITUTES 147
12.7 OTHERS 148
13 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150
13.1 OVERVIEW 151
13.2 DIRECT TENDER 154
13.3 RETAIL SALES 154
14 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 156
14.1 EUROPE 157
14.1.1 GERMANY 169
14.1.2 UNITED KINGDOM 175
14.1.3 FRANCE 181
14.1.4 ITALY 187
14.1.5 SPAIN 193
14.1.6 RUSSIA 199
14.1.7 NETHERLANDS 205
14.1.8 SWITZERLAND 211
14.1.9 BELGIUM 217
14.1.10 TURKEY 223
14.1.11 REST OF EUROPE 229
15 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 230
15.1 COMPANY SHARE ANALYSIS: EUROPE 230
16 SWOT ANALYSIS 231
17 COMPANY PROFILE 232
17.1 CANON MEDICAL SYSTEMS CORPORATION. 232
17.1.1 COMPANY SNAPSHOT 232
17.1.2 REVENUE ANALYSIS 232
17.1.3 COMPANY SHARE ANALYSIS 233
17.1.4 PRODUCT PORTFOLIO 233
17.1.5 RECENT DEVELOPMENT 233
17.2 SYSMEX CORPORATION 234
17.2.1 COMPANY SNAPSHOT 234
17.2.2 REVENUE ANALYSIS 234
17.2.3 COMPANY SHARE ANALYSIS 235
17.2.4 PRODUCT PORTFOLIO 235
17.2.5 RECENT DEVELOPMENT 235
17.3 EPIGENOMICS AG. 236
17.3.1 COMPANY SNAPSHOT 236
17.3.2 REVENUE ANALYSIS 236
17.3.3 COMPANY SHARE ANALYSIS 237
17.3.4 PRODUCT PORTFOLIO 237
17.3.5 RECENT DEVELOPMENT 237
17.4 MYRIAD GENETICS, INC.. 238
17.4.1 COMPANY SNAPSHOT 238
17.4.2 REVENUE ANALYSIS 238
17.4.3 COMPANY SHARE ANALYSIS 239
17.4.4 PRODUCT PORTFOLIO 239
17.4.5 RECENT DEVELOPMENT 239
17.5 F. HOFFMANN- LA ROCHE LTD 240
17.5.1 COMPANY SNAPSHOT 240
17.5.2 REVENUE ANALYSIS 240
17.5.3 COMPANY SHARE ANALYSIS 241
17.5.4 PRODUCT PORTFOLIO 241
17.5.5 RECENT DEVELOPMENT 241
17.6 ABBOTT 242
17.6.1 COMPANY SNAPSHOT 242
17.6.2 REVENUE ANALYSIS 242
17.6.3 PRODUCT PORTFOLIO 243
17.6.4 RECENT DEVELOPMENT 243
17.7 AGILENT TECHNOLOGIES, INC. 244
17.7.1 COMPANY SNAPSHOT 244
17.7.2 REVENUE ANALYSIS 244
17.7.3 PRODUCT PORTFOLIO 245
17.7.4 RECENT DEVELOPMENT 245
17.8 BD 246
17.8.1 COMPANY SNAPSHOT 246
17.8.2 REVENUE ANALYSIS 246
17.8.3 PRODUCT PORTFOLIO 247
17.8.4 RECENT DEVELOPMENT 247
17.9 BIOMERIEUX 248
17.9.1 COMPANY SNAPSHOT 248
17.9.2 PRODUCT PORTFOLIO 248
17.9.3 RECENT DEVELOPMENT 248
17.10 BIO-RAD LABORATORIES, INC. 249
17.10.1 COMPANY SNAPSHOT 249
17.10.2 REVENUE ANALYSIS 249
17.10.3 PRODUCT PORTFOLIO 250
17.10.4 RECENT DEVELOPMENT 250
17.11 DIASORIN S.P.A. 251
17.11.1 COMPANY SNAPSHOT 251
17.11.2 REVENUE ANALYSIS 251
17.11.3 PRODUCT PORTFOLIO 252
17.11.4 RECENT DEVELOPMENTS 252
17.12 EXACT SCIENCES CORPORATION 253
17.12.1 COMPANY SNAPSHOT 253
17.12.2 REVENUE ANALYSIS 253
17.12.3 PRODUCT PORTFOLIO 254
17.12.4 RECENT DEVELOPMENTS 254
17.13 FONAR CORP. 255
17.13.1 COMPANY SNAPSHOT 255
17.13.2 REVENUE ANALYSIS 255
17.13.3 PRODUCT PORTFOLIO 256
17.13.4 RECENT DEVELOPMENT 256
17.14 HOLOGIC INC. 257
17.14.1 COMPANY SNAPSHOT 257
17.14.2 REVENUE ANALYSIS 257
17.14.3 PRODUCT PORTFOLIO 258
17.14.4 RECENT DEVELOPMENT 258
17.15 ILLUMINA, INC. 259
17.15.1 COMPANY SNAPSHOT 259
17.15.2 REVENUE ANALYSIS 259
17.15.3 PRODUCT PORTFOLIO 260
17.15.4 RECENT DEVELOPMENT 260
17.16 KONINKLIJKE PHILIPS N.V. 261
17.16.1 COMPANY SNAPSHOT 261
17.16.2 REVENUE ANALYSIS 261
17.16.3 PRODUCT PORTFOLIO 262
17.16.4 RECENT DEVELOPMENT 262
17.17 MEDONICA CO. LTD 263
17.17.1 COMPANY SNAPSHOT 263
17.17.2 PRODUCT PORTFOLIO 263
17.17.3 RECENT DEVELOPMENT 263
17.18 MERCK KGAA 264
17.18.1 COMPANY SNAPSHOT 264
17.18.2 REVENUE ANALYSIS 264
17.18.3 PRODUCT PORTFOLIO 265
17.18.4 RECENT DEVELOPMENTS 265
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 266
17.19.1 COMPANY SNAPSHOT 266
17.19.2 PRODUCT PORTFOLIO 266
17.19.3 RECENT DEVELOPMENT 266

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.